NantHealth, which provides healthcare data solutions and plans to launch a new cancer diagnostic, raised $91 million by offering 6.5 million shares at $14, the midpoint of the range of $12.50 to $15.50. Existing shareholders, including CEO Patrick Soon-Shiong and Celgene (Nasdaq: CELG), had indicated an interest in purchasing up to $70 million (77%) of the IPO. NantHealth plans to list on the Nasdaq under the symbol NH. Jefferies and Cowen & Company acted as lead managers on the deal.
